OpGen (OPGN)
(Delayed Data from NSDQ)
$2.54 USD
-0.52 (-16.93%)
Updated Jun 3, 2024 03:59 PM ET
After-Market: $2.64 +0.10 (3.86%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth B Momentum D VGM
Brokerage Reports
0 items in cart
OpGen, Inc. [OPGN]
Reports for Purchase
Showing records 81 - 100 ( 106 total )
Company: OpGen, Inc.
Industry: Medical Services
Acuitas Urine Specimen Data Presented at ASM Microbe 2018; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
2018 1Q Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
Acuitas Analytical Validation Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
Positive Testing Results Lead to Market Entry in Colombia; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
Containing Unusual Resistance is a Pressing Need; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
2017 Results Reported; Acuitas Gene Panel 510(k) Submission in 4Q18; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
Reverse Stock Split and Financing Completed; Reiterate Buy and Adjusting Price Target to $9
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
Q3 results positive; AMR gene panel set to launch
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: OpGen, Inc.
Industry: Medical Services
3Q17 Financial Results In-Line; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
CDC Contract Awarded for Antimicrobial Stewardship; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
Acuitas AMR Gene Panel Data Presented; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Analyst: SELVARAJU R
Company: OpGen, Inc.
Industry: Medical Services
First Acuitas Rapid Test to Launch in 1H 2018; 2Q17 Financial Results Reported; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: OpGen, Inc.
Industry: Medical Services
First Acuitas Rapid Test to Launch in 1H 2018; 2Q17 Financial Results Reported; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: OpGen, Inc.
Industry: Medical Services
Acuitas MDRO Gene Test Approved in NY; Financing Completed; Reiterate Buy and Lowering Price Target to $1
Provider: Rodman & Renshaw, Co.
Company: OpGen, Inc.
Industry: Medical Services
Acuitas MDRO Gene Test Approved in NY; Financing Completed; Reiterate Buy and Lowering Price Target to $1
Provider: H.C. Wainwright & Co., Inc.
Company: OpGen, Inc.
Industry: Medical Services
We are initiating coverage on OPGN shares with a BUY rating and 12-18 month price target of $2.00 per share.
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R
Company: OpGen, Inc.
Industry: Medical Services
QuickFISH Revenue Eroding; Positive mAST Preliminary Data; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: OpGen, Inc.
Industry: Medical Services
QuickFISH Revenue Eroding; Positive mAST Preliminary Data; Reiterate Buy
Provider: H.C. Wainwright & Co., Inc.
Company: OpGen, Inc.
Industry: Medical Services
QuickFISH Revenue Flat; Pipeline Reorganized; Reiterate Buy and Adjusting Price Target to $2.00
Provider: Rodman & Renshaw, Co.
Company: OpGen, Inc.
Industry: Medical Services
QuickFISH Revenue Flat; Pipeline Reorganized; Reiterate Buy and Adjusting Price Target to $2.00
Provider: H.C. Wainwright & Co., Inc.